Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Although many genes, such as p53 and Rb1, have been shown to be mutated, deregulation of the canonical Wnt/β-catenin signaling pathway is frequently observed in OS.
|
31595984 |
2020 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
MicroRNA-504 modulates osteosarcoma cell chemoresistance to cisplatin by targeting p53.
|
30675226 |
2019 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The co-occurrence of cellular aneuploidy, complex chromosomal rearrangements and p53 dysfunction is a striking feature of some osteosarcomas.
|
30508038 |
2019 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Anti-cancer drug adriamycin (ADR) treatment induced cell death in <i>p53</i>-wild-type human osteosarcoma U2OS cells, and this was accompanied by a remarkable accumulation of p53 and γH2AX.
|
30868056 |
2019 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
At advanced ages, p53 mKO mice began to die prematurely and had an increased incidence of osteosarcoma, precluding analyses of muscle mass and function in very old p53 mKO mice.
|
31465716 |
2019 |
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
A polysaccharide from Enterobacter cloacae induces apoptosis of human osteosarcoma cells through the activation of p53 and mitochondrial intrinsic pathway.
|
30336239 |
2019 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
By utilizing the clinical information in GSE21257, 10 critical genes associated with osteosarcoma prognosis were obtained, including CTP synthase 2 (CTPS2), tumor protein p53 inducible protein 3 (TP53I3) and solute carrier family 1 member 1 (SLC1A1).
|
31173206 |
2019 |
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Western blot was conducted to detect the expression of p53 after the knockdown of SNHG7 in osteosarcoma cells.
|
31114984 |
2019 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Aberrant expression of the transcription factor, runt-related transcription factor 2 (RUNX2), is a key pathological feature in osteosarcoma and associated with loss of p53 and miR-34 expression.
|
30637720 |
2019 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Furthermore, LINC01116 is involved in the development of osteosarcoma by binding to EZH2 to regulate expressions of PTEN and p53.
|
31486480 |
2019 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 structural rearrangements have been previously reported in a significant subset of osteosarcomas, where they result in loss of p53 protein expression by immunohistochemistry.
|
31216325 |
2019 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study showed that the p53 and p38α MAPK signal axis facilitated HOXA5's role in inhibiting growth and stimulating apoptosis of osteosarcoma cells.
|
30521886 |
2019 |
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Note that this action is independent of p53 status, because VCA-1 induced similar levels of apoptosis in two different panels of cell lines (HCT116 p53- wild-type vs. HCT116 p53-knockout colon cancer cells, and p53-expressing U2OS vs. p53-deficient saos2 osteosarcoma cancer cells).
|
29773887 |
2019 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
In the present meta-analysis, we aimed to elucidate the associations of TP53 rs1042522 genetic polymorphism with the risk of osteosarcoma or Ewing sarcoma.
|
30833364 |
2019 |
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
We have also demonstrated that the knock-out or inhibition of mutant TP53 decreased the expression of the oncogene IGF-1R, anti-apoptotic proteins Bcl-2, and Survivin in osteosarcoma cells.
|
30667081 |
2019 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Although mutations in TP53 were thought to be relatively low in sarcomas, modern techniques including whole-genome sequencing have recently illuminated unappreciated alterations in TP53 in osteosarcoma.
|
31276706 |
2019 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed modulatory effects on the cell cycle by viscumTT in three osteosarcoma cell lines with various TP53 statuses.
|
29636527 |
2018 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Importantly, MG-63 human osteosarcoma xenograft growth in nude mice was significantly suppressed in vivo through triggering apoptosis and p53 phosphorylation.
|
29323455 |
2018 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Here we looked for novel genes potentially (co)regulated by p53 and NF-κB using integrative genomics screening in human osteosarcoma U2-OS cells irradiated with a high dose (4 and 10 Gy).
|
30419821 |
2018 |
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
While p53 and Rb inactivation occurs in most osteosarcomas, the landscape of associated driver mutations has proved extensive.
|
29435436 |
2018 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
This study found an association between alterations in the TP53 gene and the synergy score for combination treatment with doxorubicin and an Src kinase inhibitor using human osteosarcoma cell lines (MG63 and U2OS) and human colon cancer cell line.
|
30124118 |
2018 |
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
After SOX4 gene silencing, the protein expression levels of Bax, Caspase-3, and P53 in osteosarcoma cells were significantly elevated, while the protein expression levels of Bcl-2, MMP2, and MMP9 were obviously decreased.
|
29038881 |
2018 |
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, the relative protein expression level of p-PI3K, p-Akt and Bcl-2 were significantly increased and the relative expression of P53 was significantly decreased in osteosarcoma cells after transfection with lncRNA-LINC00628.
|
30280767 |
2018 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
ONZIN Upregulation by Mutant p53 Contributes to Osteosarcoma Metastasis Through the CXCL5-MAPK Signaling Pathway.
|
30041188 |
2018 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
How mutation of p53 enables OS development from osteoblastic lineage cells is poorly understood.
|
30154459 |
2018 |